glp-1 receptors in the body receptor biology: structure, signaling, and distribution Glucagon-like peptide 1(GLP-1) receptor agonists

, , : , , ,

Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension

Subclinical hepatic encephalopathy may not feature any symptoms beyond abnormal behavior on psychometric tests or symptoms that are nonspecific in nature

The advancement opens new possibilities for over 100 million Americans living with obesity

Firms on the Green List of the alert, however, are exempt

All GLP-1s promote weight loss, but semaglutide (particularly at higher doses used for weight loss) and tirzepatide have demonstrated the most significant weight loss effects